crispr-pd1 modified tumor infiltrating lymphocytes

CRISPR-PD1 modified tumor infiltrating lymphocytes are autologous T cells derived from tumors (TILs) that have been gene-edited using CRISPR/Cas9 technology to knock out the programmed cell death protein 1 (PD-1) gene. The PD-1 protein acts as an immune checkpoint, reducing T cell activity in the tumor microenvironment. By disrupting PD-1, these genetically modified TILs are less susceptible to immune inhibitory signals from tumors expressing PD-L1, leading to enhanced antitumor cytotoxicity, increased cytokine production, and greater tumor infiltration. This therapy is being developed primarily for patients with advanced solid tumors, including melanoma, colorectal cancer, and head-and-neck cancers, and represents an investigational cell therapy approach aiming to improve the efficacy of adoptive cell therapy and overcome resistance to conventional anti-PD-1 antibody therapeutics. The modification is performed ex vivo using non-viral, non-plasmid-based CRISPR methods, and the resulting product consists of expanded, PD-1-deficient TILs suitable for infusion back into the patient[3][4][5][6][7]. Early-phase clinical trials are evaluating its safety and feasibility[5][6].

Other names

CRISPR-PD1 modified TILsCRISPR-PD-1 modified TILsCRISPR-PD 1 modified TILsCRISPR-TILsPD1-deficient TILsPD-1-deficient TILsPD 1-deficient TILs